Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 70Lymphoma, Large B-Cell, Diffuse 67Lymphoma 66Lymphoma, Follicular 59Leukemia, Lymphocytic, Chronic, B-Cell 58Lymphoma, B-Cell, Marginal Zone 30Burkitt Lymphoma 30Waldenstrom Macroglobulinemia 24Lymphoma, Mantle-Cell 24Lymphoma, B-Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Recurrence 17Hodgkin Disease 12Neoplasms 10Lymphoma, Large-Cell, Immunoblastic 10Multiple Myeloma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Acute 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Mycosis Fungoides 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Hairy Cell 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Intraocular Lymphoma 5Dendritic Cell Sarcoma, Interdigitating 5

Interventions

Gene Expression Profiling 2Biopsy 2ibrutinib 1fludarabine phosphate 1fludarabine 1emvododstat 1efineptakin alfa 1Zidovudine 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Therapeutics 1Taxes 1Specimen Handling 1Rituximab 1Polymerase Chain Reaction 1Paclitaxel 1Nivolumab 1Methotrexate 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Immunohistochemistry 1Genes 1Flow Cytometry 1Erlotinib Hydrochloride 1Dexamethasone 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HIV Infections × Rituximab × Clear all
NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

French National Agency for Research on AIDS and Viral Hepatitis

Phase 2 Terminated
25 enrolled
LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡